The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Feature|Articles|March 2, 2024
- Pharmaceutical Technology, March 2024
- Volume 48
- Issue 3
- Pages: 10
VMC-100-gallon VersaMix Multi-Shaft Mixer
Author(s)Pharmaceutical Technology Editors
The ROSS line of VersaMix multi-shaft mixers are built for longevity, speed, and efficiency.
Capable of processing viscous solutions, dispersions, suspensions, and emulsions with viscosities in the hundreds of thousands of centipoise, the ROSS line of VersaMix multi-shaft mixers are built for longevity, speed, and efficiency. The pictured ROSS VMC-100 is designed for vacuum operation up to 29.5”Hg and supplied with interchangeable 100-gal mix cans, each fabricated with a 50-psig American Society of Mechanical Engineers code-stamped jacket for heating/cooling via glycol. The custom electro-hydraulic system is engineered to fully raise the motor drive in 15 seconds.
The VMC-100 features three independently driven agitators, including a three-wing anchor agitator equipped with optional hinged sidewall and bottom Teflon scrapers to improve heat transfer across the jacketed vessel. The high shear mixer is capable of introducing powders sub-surface while the batch is low in viscosity. Through the ROSS solids liquid injection manifold (SLIM) technology, raw material additions are less dusty and lumps or fish eyes are avoided. The 8”-diameter high speed disperser continues to apply shear as the batch increases in viscosity.
Articles in this issue
over 2 years ago
Reshaping Dosage Formsover 2 years ago
Development of Gamma-Delta T-Cell Therapiesover 2 years ago
Automating the Future of Fill/Finishover 2 years ago
Frontrunners in Bispecific Antibodiesover 2 years ago
Updating Swiss Regulatory Processes in 2024over 2 years ago
Budget Benefitover 2 years ago
First in Line on Catalent’s LineRelated to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.